Article

Validity and utility of blood tumor mutational burden is dependent on circulating tumor DNA shed

2023-02-07

Abstract excerpt

<title>Abstract</title> <p>Tumor mutational burden (TMB) is a genomic biomarker associated with the benefits of immune checkpoint inhibitors (ICIs). Detection of elevated blood TMB (bTMB) in circulating tumor DNA represents a compelling noninvasive approach. However, the validity and utility of this emerging biomarker across cancer types has not been established. To better understand bTMB landscape, a preliminary...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 685d9a8b-2346-57a5-a67e-a64252482fa6
DOI: 10.21203/rs.3.rs-2516675/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Validity and utility of blood tumor mutational burden is dependent on circulating tumor DNA shedDOI 10.21203/rs.3.rs-2516675/v1Read

Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREENSemantic proximity Read

Assessment of blood-based tumor mutational burden on clinical outcomes in advanced breast and prostate cancer treated with immune checkpoint inhibitorsSemantic proximity Read

Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure.Semantic proximity Read

High tumor mutational burden predicts survival and responses to ICI immunotherapy in a cancer-dependent mannerSemantic proximity Read

TMBpred: A bioinformatics tool for precise prediction of the Tumor Mutation Burden in 14 cancer typesSemantic proximity Read

Tumor Mutational Burden as a Predictive Biomarker in Solid TumorsSemantic proximity Read

Viewpoint: The Current Advances and Future Optimization of Blood-based Tumor Mutation Burden as a Biomarker for Cancer ImmunotherapySemantic proximity Read

Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS AssaysSemantic proximity Read

Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.Semantic proximity Read

Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkersSemantic proximity Read

Noninvasive MRD monitoring and profiling of clonal evolution by ctDNA in patients with advanced cancers treated within molecular tumor boardsSemantic proximity Read

Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer ApproachSemantic proximity Read